Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Trends in Patch Testing With the Mayo Clinic Standard Series, 2011–2015

Veverka, Kevin K., MD*; Hall, Matthew R., MD; Yiannias, James A., MD; Drage, Lisa A., MD§; el-Azhary, Rokea A., MD, PhD§; Killian, Jill M., BS; Johnson, Janis S., RN; Nordberg Linehan, Diane L., RN; Singh, Nidhi, RN; Davis, Mark D. P., MD§

doi: 10.1097/DER.0000000000000411
STUDIES

Background Patch testing to a standard (baseline) series of allergens is the screening tool used to identify culprit allergens in patients with contact dermatitis. The allergens and concentrations used in a standard series are constantly evolving to be most relevant to the patients being patch tested.

Objective The aim of this study was to analyze the 2011–2015 patch test results of the Mayo Clinic standard series.

Methods We retrospectively reviewed patch test reactions of standard series allergens from 2011 through 2015 and compared these results with the 2011–2012 and 2013–2014 North American Contact Dermatitis Group (NACDG) reports.

Conclusions Of 2582 patients included, 1566 (60.7%) had at least 1 positive reaction, and 516 (20.0%) had at least 1 irritant reaction. The 15 allergens with the highest reaction rates (from highest to lowest) were nickel sulfate hexahydrate, methylisothiazolinone, Myroxylon pereirae resin, neomycin sulfate, cobalt (II) chloride hexahydrate, benzalkonium chloride, fragrance mix I, potassium dichromate, bacitracin, methylchloroisothiazolinone/methylisothiazolinone, carba mix, formaldehyde, p-phenylenediamine, quaternium-15, and methyldibromo glutaronitrile. Twelve (80%) of these allergens were also in the top 15 of the most recent NACDG report; the 3 allergens not in the NACDG top 15 allergens were potassium dichromate, benzalkonium chloride, and methyldibromo glutaronitrile (the latter 2 allergens are not included in their series).

From the *Mayo Clinic School of Medicine;

Department of Dermatology, Mayo Clinic, Jacksonville, FL;

Department of Dermatology, Mayo Clinic, Scottsdale, AZ; and

§Department of Dermatology and

Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.

Address reprint requests to Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail: davis.mark2@mayo.edu.

K.K.V. is a student, Mayo Clinic School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.

Mayo Clinic does not endorse specific products or services included in this article.

The authors have no funding or conflicts of interest to declare.

© 2018 American Contact Dermatitis Society
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website